Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588536 · ClinicalTrials.gov registry record · Phase 2
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00588536 is a Phase 2 study of Langerhans Cell Histiocytosis that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5 participants, below the 1,138-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00588536, a Phase 2 study of Langerhans Cell Histiocytosis, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).
Conditions Studied
Interventions
- DRUG Leucovorin Calcium
- DRUG Methotrexate
- DRUG 6-Thioguanine
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 1995-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588536
The ClinicalTrials.gov registry entry for NCT00588536 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,138-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (100% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 3 interventions - of which Leucovorin Calcium is the first listed.
NCT00588536 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00588536 about?
NCT00588536 is a clinical study titled "Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH". The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).
What is the current status of trial NCT00588536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 1995-01. Estimated completion is 2009-06.
What conditions does trial NCT00588536 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT00588536?
The interventions under investigation include: Leucovorin Calcium (DRUG), Methotrexate (DRUG), 6-Thioguanine (DRUG).
Who is sponsoring clinical trial NCT00588536?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588536 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.